Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 605 participants.

Also called NCT03895502

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 605 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03895502
Other papers using this trial's data
  • Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial Circulation, 2023-11-21 DOI, PubMed 37638968
  • Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study European heart journal. Cardiovascular pharmacotherapy, 2024-08-14 DOI, PubMed 38650055, PMC11323369 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03895502. Randomized; no masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2023-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
Acronym
ONCO DVT
Condition
Venous Thrombosis
Condition
Neoplasms
Condition
Anticoagulant
Intervention (Drug)
12-month Edoxaban
Intervention (Drug)
3-month Edoxaban
Lead sponsor
Takeshi Morimoto (class: other)

Record details

Record id
cardio:ct-nct03895502
Content hash
dac19df87ca71e7006d26fc5dad209b8911a89acb0ce65d522fac9f2a2d34245